MEMORIA CIENTIFICA 2022

Servicio de Dermatología

Hospital Universitario San Cecilio

 

PUBLICACIONES

 

Dermatología General

 

  1. Català A, Clavo-Escribano P, Riera-Monroig J, Martín-Ezquerra G, Fernandez- Gonzalez P, Revelles-Peñas L, Simon-Gozalbo A, Rodríguez-Cuadrado FJ, Castells VG, de la Torre Gomar FJ, Comunión-Artieda A, de Fuertes de Vega L, Blanco JL, Puig S, García-Miñarro ÁM, Fiz Benito E, Muñoz-Santos C, Repiso-Jiménez JB, López Llunell C, Ceballos-Rodríguez C, García Rodríguez V, Castaño Fernández JL, Sánchez-Gutiérrez I, Calvo-López R, Berna-Rico E, de Nicolás-Ruanes B, Corella Vicente F, Tarín Vicente EJ, de la Fernández de la Fuente L, Riera-Martí N, Descalzo-Gallego MA, Grau-Perez M, García-Doval I, Fuertes I. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases. Br J Dermatol. 2022 Aug 2.
  2. Llamas-Molina JM, De la Torre-Gomar FJ, Carrero-Castaño A, Gil-Villalba A, Prados-Carmona Á, Ruiz-Villaverde R. Acrokeratosis verruciformis of Hopf: dermoscopy approach in dark skin patients. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):e944-e945.
  3. Gimeno Castillo J, De la Torre Gomar FJ, Saenz Aguirre A. Extensive condiloma acuminata: Complete remission after oral isotretinoin and topical imiquimod. A successful combination? Dermatol Ther. 2022 Jul;35(7):e15572.
  4. Vega-Castillo JJ, Saenz-Guirado S, Vega-Castillo ML, Ruiz-Villaverde R. Umbilical Endometriosis: A New Dermoscopic Pattern. Dermatol Pract Concept. 2022 Jan 1;12(1):e2022023.
  5. Llamas-Molina JM, Navarro-Triviño FJ, Ruiz-Villaverde R. Old World Cutaneous Leishmaniasis: Successful response to topical imiquimod. Sultan Qaboos Univ Med J. 2022 Aug;22(3):426-427.
  6. Navarro-Triviño FJ, Ruiz-Villaverde R. Carbamezepine-Induced Acquired Multifocal Keratoderma. Actas Dermosifiliogr. 2022 Jun;113(6):652-653.
  7. Prados-Carmona Á, Gómez-Valcárcel JJ, Velasco-Amador JP, Martin-Castro A, Navarro-Triviño FJ. Cutaneous leishmaniasis over a tattoo mimicking keratoacanthoma in Southern Europe. J Eur Acad Dermatol Venereol. 2022 May;36(5):e387-e389.
  8. Navarro-Triviño FJ, Moreno-Higueras M. Keratoderma and dental involvement. Rev Clin Esp (Barc). 2022 Jan;222(1):54-55.
  9. Prados-Carmona A, Prados-Carmona JJ, Gálvez-Moreno M, Ruiz-Villaverde R. Are cyclosporine eye drops a suitable treatment in ocular rosacea? J Dermatolog Treat. 2022 Oct 19:1-3.
  10. Prados-Carmona A, Fuentes-Jimenez F, Roman de Los Reyes R, García-Rios A, Rioja-Bravo J, Herruzo-Gomez E, Perez-Martinez P, Lopez-Miranda J, Delgado-Lista J. A Pilot Study on the Feasibility of Developing and Implementing a Mobile App for the Acquisition of Clinical Knowledge and Competencies by Medical Students Transitioning from Preclinical to Clinical Years. Int J Environ Res Public Health. 2022 Feb 27;19(5):2777.
  11. Ayén-Rodríguez A, Llamas-Molina JM, Gálvez-Moreno M, Ruiz-Villaverde R. Cold urticarial vasculitis successfully treated with omalizumab. Int J Dermatol. 2022 Feb 15. doi: 10.1111/ijd.16133.
  12. Pérez-López I, Moyano-Bueno D, Ruiz-Villaverde R. Bullous pemphigoid and COVID-19 vaccine. Med Clin (Engl Ed). 2021 Nov 26;157(10):e333-e334.
  13. Conde-Ferreirós A, Moyano-Bueno D, Santos-Briz Á, Revelles-Peñas L, Revilla-Nebreda D, Becerril-Andrés S, Román-Curto C, Cañueto J. Clinical and histopathological evaluation of 50 acantholytic cutaneous squamous cell carcinomas: Analysis outcome in a retrospective case-control study. J Cutan Pathol. 2022 Feb;49(2):133-138.
  14. Llamas-Molina JM, Ruiz-Villaverde R. Cobblestone plaques on the lateral side of the neck. Int J Dermatol. 2022 Jul;61(7):821-822.
  15. Martín Enguix D, Gil-Villalba A, Ruiz-Villaverde R. Aparición simultánea de granulomas en diferentes tatuajes: una forma inusual de sarcoidosis de las cicatrices [Simultaneous appearance of granulomas in different tattoos: An unusual form of scar sarcoidosis]. Semergen. 2022 Oct 6;49(2):101842.
  16. Ruiz-Villaverde R, Rivera-Izquierdo M, Gil-Villalba A, Pegalajar-García MD, Pérez-Rojas J, Soler-Iborte E, Valero-Ubierna MC. Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers. Int J Dermatol. 2022 Oct;61(10):1289-1293.
  17. Ródenas-Herranz T, Linares-González L, Ruiz-Villaverde R. Long-Standing Gouty Panniculitis. Actas Dermosifiliogr. 2022 Jun 23:S0001-7310(22)00593-2.
  18. Linares-Gonzalez L, Ródenas-Herranz T, Ruiz-Villaverde R. Spiny Keratoderma as a Paraneoplastic Condition in Clear Cell Renal Cell Carcinoma. Actas Dermosifiliogr. 2022 May;113(5):514-515.
  19. Linares-Gonzalez L, Ayén-Rodriguez A, Ruiz-Villaverde R. Long-standing Proliferating Trichilemmal Cyst. Actas Dermosifiliogr. 2022 Apr;113(4):417.
  20. Pérez-López I, Gil-Villalba A, Ruiz-Villaverde R. Perniosis-like lesions after vaccination with mRNA against COVID-19. Med Clin (Engl Ed). 2022 Feb 25;158(4):189-190.
  21. Català A, Muñoz-Santos C, Galván-Casas C, Roncero Riesco M, Revilla Nebreda D, Solá-Truyols A, Giavedoni P, Llamas-Velasco M, González-Cruz C, Cubiró X, Ruíz-Villaverde R, Gómez-Armayones S, Gil Mateo MP, Pesqué D, Marcantonio O, Fernández-Nieto D, Romaní J, Iglesias Pena N, Carnero Gonzalez L, Tercedor-Sanchez J, Carretero G, Masat-Ticó T, Rodríguez-Jiménez P, Gimenez-Arnau AM, Utrera-Busquets M, Vargas Laguna E, Angulo Menéndez AG, San Juan Lasser E, Iglesias-Sancho M, Alonso Naranjo L, Hiltun I, Cutillas Marco E, Polimon Olabarrieta I, Marinero Escobedo S, García-Navarro X, Calderón Gutiérrez MJ, Baeza-Hernández G, Bou Camps L, Toledo-Pastrana T, Guilabert A. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol. 2022 Jan;186(1):142-152.

 

 

 

Unidad de Laserterapia

 

  1. Naranjo Díaz MJ, Ródenas-Herranz T, Espadafor-Lopez B, Ruiz-Villaverde R. Satisfactory Response to Pulsed Dye Laser Treatment of Facial Erythema in a Patient with Amyopathic Dermatomyositis. Actas Dermosifiliogr. 2022 Sep 14:S0001-7310(22)00788-8.
  2. Ayen-Rodriguez A, Naranjo-Diaz MJ, Ruiz-Villaverde R. Laser Therapy for the Treatment of Actinic Cheilitis: A Systematic Review. Int J Environ Res Public Health. 2022 Apr 11;19(8):4593. doi: 10.3390/ijerph19084593. PMID: 35457467; PMCID: PMC9028420.

Unidad de Terapia Fotodinamica

 

  1. .Sáenz-Guirado S, Cuenca-Barrales C, Vega-Castillo J, Linares-Gonzalez L, Ródenas-Herranz T, Molina-Leyva A, Ruiz-Villaverde R. Combined versus conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study. Photodermatol Photoimmunol Photomed. 2022 Jul;38(4):334-342.

Unidad de Dermatologia Pediátrica

 

  1. Pegalajar García MD, Ródenas Herranz T, Pérez López I, Ramos Pleguezuelos FM, Ruiz Villaverde R. Asymptomatic nodules in body folds of a newborn. Pediatr Dermatol. 2022 May;39(3):458-460.
  2. Vega-Castillo JJ, Martín-Santiago A. RF - Diagnosis and Management of Incontinentia Pigmenti: An Update. Actas Dermosifiliogr. 2022 Jun;113(6):624-626.

Unidad de Melanoma y Oncologia Cutánea

 

  1. Rosés-Gibert P, Podlipnik S, de la Torre Gomar FJ, Saenz Aguirre A, Gimeno Castillo J, González Pérez R, Puig S. Incidence of Melanoma in the Basque Province of Álava, Spain, From 2015 to 2018: A Descriptive Study. Actas Dermosifiliogr. 2022 Feb;113(2):178-182.

 

Unidad de Fototerapia

 

  1. Gil-Villalba A, de la Torre-Gomar FJ, Navarro-Triviño FJ, Ruiz-Villaverde R. Successful treatment of follicular mucinosis with low-dose UVA1 phototherapy. Dermatol Ther. 2022 Oct;35(10):e15773.

 

Unidad de Inmunoalergia

 

  1. Saenz Aguirre A, de la Torre Gomar FJ, Rosés-Gibert P, González-Pérez R. Usefulness of Patch Tests in the Management of Generalized and/or Disseminated Eczema: Experience at a Tertiary Hospital. Actas Dermosifiliogr. 2022 Feb;113(2):213-215.
  2. Navarro-Triviño FJ, Pegalajar-García, Gil-Villalba A, Ruiz-Villaverde R.Allergic Contact Dermatitis Due to Minoxidil in a Patient With Alopecia Areata.nActas Dermosifiliogr. 2022 Oct 11:S0001-7310(22)00883-3. English, Spanish. doi:
  3. Navarro-Triviño FJ, Ruiz-Villaverde R. [Translated article] Changes in Liver Viral Load in Hepatitis B Virus Infection During Treatment of Chronic Urticaria With Omalizumab: Is There a Pathophysiologic Relationship Between the 2 Diagnostic Entities? Actas Dermosifiliogr. 2022 Oct 10:S0001-7310(22)00878-X.
  4. Alcantara-Luna S, Ruiz-Villaverde R, Domínguez-Cruz J, Galán-Gutiérrez M, Navarro-Triviño F, Pereyra-Rodriguez JJ, Armario-Hita JC. Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning. Int J Environ Res Public Health. 2022 Aug 29;19(17):10753.
  5. Ruiz-Villaverde R, Domínguez-Cruz J, Navarro-Triviño FJ, Galán-Gutiérrez M, Armario-Hita JC, Pereyra-Rodriguez JJ. Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders). Life (Basel). 2022 Aug 4;12(8):1192.
  6. Ayen-Rodríguez A, Pereyra-Rodríguez JJ, Navarro-Triviño FJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, Vilar-Palomo S, Armario-Hita JC, Ruiz- Villaverde R. Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review. Life (Basel). 2022 Jul 30;12(8):115
  7. Navarro-Triviño FJ, Ruiz-Villaverde R. Photosensitive rash induced by nivolumab. An Bras Dermatol. 2022 Sep-Oct;97(5):648-650.
  8. Llamas-Molina JM, Navarro-Triviño FJ, Ruiz-Villaverde R. What Dermatologists Should Know About Thiazides. Actas Dermosifiliogr. 2022 May;113(5):498-504.
  9. Gatica-Ortega ME, Mowitz M, Navarro-Triviño FJ, Gargallo-Quintero AB, Carbonero-Jiménez L, Heras-Mendaza F, Herreros-Montejano F, Sanz-Sánchez T, Borrego L, Bruze M, Svedman C, Pastor-Nieto MA. Nonoccupational Allergic Contact Dermatitis to 4-Acryloylmorpholine in Smartwatch Screen Protectors Glue. Dermatitis. 2022 Jun 8. doi: 10.1097/DER.0000000000000888.
  10. Navarro-Triviño FJ, Ruiz-Villaverde R. Patterns of Head and Neck Dermatitis in Patients Treated With Dupilumab: Differential Diagnosis and Treatment. Actas Dermosifiliogr. 2022 Mar;113(3):219-221.
  11. Navarro-Triviño FJ, Prados-Carmona Á, Ruiz-Villaverde R. Systemic allergic contact dermatitis caused by tea tree oil in a cream for treatment of molluscum contagiosum. Contact Dermatitis. 2022 Sep;87(3):285-287.
  12. Navarro-Triviño FJ, Ruiz-Villaverde R. Allergic contact dermatitis in a psoriasis patient caused by cetylstearyl alcohol. Contact Dermatitis. 2022 Sep;87(3):283-285.
  13. Navarro-Triviño FJ, Ayén-Rodríguez Á, Ruiz-Villaverde R. Allergic contact dermatitis caused by capryloyl glycine in an atopic dermatitis patient. Australas J Dermatol. 2022 Aug;63(3):e259-e261.
  14. Ruiz-Villaverde R, Navarro-Triviño FJ. Contact Vitiligo Following Allergic contact Dermatitis. Sultan Qaboos Univ Med J. 2022 Feb;22(1):152-153.
  15. Navarro-Triviño FJ, Cassini-Gómez de Cádiz VA. Allergic contact dermatitis caused by Intrasite Conformable and Cutimed Sorbact wound dressings. Contact Dermatitis. 2022 Jun;86(6):562-564.
  16. Navarro-Triviño FJ, Ayén-Rodríguez Á. Study of Hypersensitivity to <i>Malassezia furfur</i> in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients? Life (Basel). 2022 Feb 16;12(2):299.
  17. Stockman A, Belpaire A, Hadshiew IM, Žemli?kova M, Vergou T, Navarro Triviño F, Márquez García A, Vasco M, Vazharova BK, Carballido F. Dermo-cosmetic spray containing Rhealba oat plantlets and Uncaria tomentosa extract in patients with mild-to-moderate cutaneous pain. J Eur Acad Dermatol Venereol. 2022 Feb;36 Suppl 4:3-11. doi: 10.1111/jdv.17876. PMID: 35174562.
  18. Navarro-Triviño FJ, Ayén-Rodríguez Á, Ruiz-Villaverde R. Contact urticaria caused by chamomile in a wet wipe. Contact Dermatitis. 2022 Jun;86(6):548-549.
  19. Navarro-Triviño FJ. Allergic contact dermatitis from shellac in an ecological hair spray occurring in a patient with frontal fibrosing alopecia. Contact Dermatitis. 2022 Jun;86(6):544-545.
  20. Linares-Gonzalez L, Lozano-Lozano I, Gutierrez-Rojas L, Ruiz-Villaverde R, Lozano-Lozano M. Sexual dysfunction in a cohort of patients with moderate-to-severe atopic dermatitis. Influence of dupilumab treatment. Int J Dermatol. 2022 May;61(5):607-610.
  21. Navarro-Triviño FJ, Ruiz-Villaverde R. Lichenoid drug eruption induced by pravastatin; it is possible to prescribe other statins? An Bras Dermatol. 2022 Nov 1:S0365-0596(22)00229-X. 

 

Unidad de Psoriasis

 

  1. Rosés Gibert P, de la Torre Gomar FJ, Saenz Aguirre A, Gimeno Castillo J, González Pérez R. Dimethyl Fumarate as Therapeutic Alternative in Moderate-to-Severe Psoriasis: Our Experience. Psoriasis (Auckl). 2022 Jun 29;12:177-185.
  2. Ruiz-Villaverde R, Velasco-Amador JP, Prados-Carmona A, Ruiz-Carrascosa JC. Switching from reference adalimumab to biosimilar. Assessment of clinical outcomes in psoriasis. Int J Dermatol. 2022 Aug 10. doi: 10.1111/ijd.16399.
  3. Vidal S, Puig L, Carrascosa-Carrillo JM, González-Cantero Á, Ruiz-Carrascosa JC, Velasco-Pastor AM. Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22, 6740. Int J Mol Sci. 2022 Feb 28;23(5):2649. doi: 10.3390/ijms23052649. Erratum for: Int J Mol Sci. 2021 Jun 23;22(13):
  4. Cuenca-Barrales C, Ruiz-Carrascosa JC, Ruiz-Villaverde R. RF - Should Striae be Considered a Predisposing Factor for Koebner Phenomenon in Psoriasis? Actas Dermosifiliogr. 2022 Feb;113(2):190-191.
  5. Ruiz-Villaverde R, Vasquez-Chinchay F, Rodriguez-Fernandez-Freire L, C Armario-Hita J, Pérez-Gil A, Galán-Gutiérrez M. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives. Life (Basel). 2022 Sep 10;12(9):1412.
  6. Ruiz-Villaverde R, Chinchay FV, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab. Dermatol Ther. 2022 Sep 17:e15835.
  7. Ruiz-Villaverde R, Rodriguez Fernandez-Freire L, Font-Ugalde P, Galan-Gutierrez M. Tildrakizumab: Efficacy, Safety and Survival in Mid-Term (52 Weeks) in Three Tertiary Hospitals in Andalucia (Spain). J Clin Med. 2022 Aug 30;11(17):5098.
  8. Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Chinchay FV, Galán-Gutiérrez M. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis. Dermatol Ther. 2022 Oct;35(10):e15760. doi: 10.1111/dth.15760.
  9. Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, Julià M, Ruiz-Villaverde R, Rodríguez Fernández-Freire L, Notario J, Llamas-Velasco M, Ferran M, Carrascosa JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. J Dermatolog Treat. 2022 Sep;33(6):2878-2880.
  10. Del Alcázar E, López-Ferrer A, Martínez-Doménech Á, Ruiz-Villaverde R, Llamas-Velasco MDM, Rocamora V, Julià M, Notario J, Fernández-Freire LR, Sahuquillo-Torralba A, Vidal D, Rivera R, Carretero G, Mateu A, de la Cueva P, Carrascosa JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatol Ther. 2022 Feb;35(2):e15231.
  11. Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, Pérez-Gil A, Galán-Gutiérrez M. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series. Int J Dermatol. 2022 Aug;61(8):1029-1033.
  12. Galán-Gutierrez M, Rodriguez-Fernandez Freire L, Ruiz-Villaverde R. Tildrakizumab: short-term efficacy and safety in real clinical practice. Int J Dermatol. 2022 Sep;61(9):e355-e357.

 

Unidad de Tricología

 

  1. Porriño-Bustamante ML, Pinedo-Moraleda FJ, Fernández-Flores Á, Montero-Vílchez T, Fernández-Pugnaire MA, Arias-Santiago S. Frontal Fibrosing Alopecia: A Histopathological Comparison of the Frontal Hairline with Normal-Appearing Scalp. J Clin Med. 2022 Jul 15;11(14):4121.
  2. Porriño-Bustamante ML, Montero-Vílchez T, Pinedo-Moraleda FJ, Fernández-Flores Á, Fernández-Pugnaire MA, Arias-Santiago S. Frontal Fibrosing Alopecia and Sunscreen Use: A Cross-sectional Study of Actinic Damage. Acta Derm Venereol. 2022 Aug 11;102:adv00757.
  3. Navarro-Triviño FJ, Ruiz-Villaverde R, Manuel Ramos-Pleguezuelos F, Vañó-Galván S. Canities Subita after Extreme Trauma Showing Positive Staining for Anti-PD-L1 Antibodies: A New Clue into Etiopathogenesis? Skin Appendage Disord. 2022 Jan;8(1):65-69.
  4. Llamas-Molina JM, Carrero-Castaño A, Ruiz-Villaverde R, Campos A. Tissue Engineering and Regeneration of the Human Hair Follicle in Androgenetic Alopecia: Literature Review. Life (Basel). 2022 Jan 14;12(1):117.
  5. Lobato-Berezo A, March-Rodríguez A, Grimalt R, Rodríguez-Lomba E, Setó-Torrent N, Pujol RM, Ruiz-Villaverde R. Mini pulse corticosteroid therapy with oral dexamethasone for moderate to severe alopecia areata: A multicentric study. Dermatol Ther. 2022 Sep 7:e15806

 

ENSAYOS CLINICOS ACTIVOS

 

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov Identifier: NCT03569293

Co-investigadores: Ricardo Ruiz Villaverde

Carácter: Europeo

Laboratorio responsable: Abbvie SA

Investigador principal Local: Jose C Ruiz Carrascosa

Iniciado en 2019, en curso (n=6, 3 en active). Open label extension 

 

Estudio fase 4 de comparación y eficacia y seguridad de Brodalumab versus Guselkumab en sujetos adultos con psoriasis en placas de moderada a grave y respuesta inadecuada a ustekinumab. Estudio Cobra

EudraCT: LP0160—510

Investigador principal: Jose Carlos Ruiz Carrascosa

Nº centro: ESP1493

Iniciado en 2021. Concluido en 2022 (n=1)

 

Psoriasis Longitudinal Assessment and Registry (PSOLAR). Registry C0168Z03. A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics

Código del protocolo: ClinicalTrials.gov Identifier: NCT00508547

Promotor: Janssen Scientific Affairs, LLC

Investigador principal: Jose Carlos Ruiz Carrascosa

Iniciado en 2020  (n=8)

 

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid Protocol Number: ARGX-113-2009 Version Number: 1.0 (Original) Compound: Efgartigimod (ARGX-113) Brief Title: A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid Study Phase: 2/3 Acronym: BALLAD

Promotor: Argenx BV

Investigador Principal: David Moyano Bueno, Ricardo Ruiz Villaverde

Iniciado en 2022 (n=1)

 

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to- Severe Plaque Psoriasis

Promotor: Janssen Scientific Affairs, LLC

Investigador principal: Jose Carlos Ruiz Carrascosa

Iniciado en 2022 (N=1)

 

Protocol Title: A Phase 4, Multi-centre, Randomized, Evaluator[1]blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients with Actinic Keratosis on the Face or Scalp.

Clinical Trial Code: M-14789-41

Sponsor Name: Almirall, S.A.

Investigador principal: Ricardo Ruiz Villaverde

Iniciado en 2022 (n=3)

 

A Phase 3, Double-Blind, Randomized, 16- Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults with Chronic Hand Eczema

Clinical Trial Code: INCB 18424-314

Sponsor Name:

Investigador principal: Francisco Navarro Triviño

Iniciado en 2022

 

LP0133-1426 “A phase 3 clinical trial to evaluate efficacy and safety of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in adolescents 12-17 years of age with moderate to severe chronic hand eczema”  

Promotor: Leo Pharma

Investigador Principal: Francisco J Navarro Triviño

Iniciado en 2022 (n=1)

 

ESTUDIOS OBSERVACIONALES NO EPA EN ACTIVO

 

Unidad de Terapia Fotodinámica

 

Terapia Fotodinámica convencional vs Terapia Fotodinámica Luz de Día + Terapia Fotodinámica Convencional

Promotor: Servicio de Dermatología. Hospital Universitario Clínico San Cecilio

FEA. Soledad Saénz Guirado

 

Sáenz-Guirado S, Cuenca-Barrales C, Vega-Castillo J, Linares-Gonzalez L, Ródenas-Herranz T, Molina-Leyva A, Ruiz-Villaverde R. Combined versus conventional photodynamic therapy with 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) for actinic keratosis: A randomized, single-blind, prospective study. Photodermatol Photoimmunol Photomed. 2021

 

Unidad de Melanomas/Oncología cutánea

 

Conservative nodal surgery (node-picking) of patients with stage III melanoma with low-burden of nodal disease (MELCONSURG MULTICENTRE COHORT)

Promotor: Hospital Universitario Virgen Macarena.

IP David Moreno Ramirez

FEA. Francisco Almazan Fernandez y Ricardo Ruiz Villaverde

 

Caracterización de las propiedades mecánicas in vivo de la piel normal frente a la sospechosa de tumores benignos y de melanoma y carcinoma escamoso y basocelular. ELASTOME

IP: José Luis Martín Rodríguez

COLABORADORES: Aurelio Martín Castro, Ricardo Ruiz Villaverde, Hirad Shamimi Noori, Jose M. Cortés, Inas H. Faris, Jorge Torres, Guillermo Rus

 

Generación de cohortes y caracterización multiómica del Síndrome de Sjögren y la Dermatitis Atópica

Promotor. Jose M Carrascosa. Hospital Germans Trias i Pujol

Colaborador. Ricardo Ruiz Villaverde

 

Dermatología General

 

Caracterización histología y molecular de la matriz extracelular en la AAF. Estudio prospectivo, abierto, no controlado

Promotor: Servicio de Dermatología. Hospital Universitario Clínico San Cecilio

FEA: Ricardo Ruiz Villaverde 

En activo

 

A prospective observational study of adult patients receiving Dupixent for atopic dermatitis

Protocol Number: OBS15990 / GLOBOSTAD

Investigador principal: Ricardo Ruiz Villaverde

En activo

 

Estudio Observacional transversal para evaluar el impacto de la urticaria crónica desde la perspectiva del paciente. Encuesta Atlas de Urticaria crónica

Promotor: Novartis

Investigador principal local: Ricardo Ruiz Villaverde

Concluido y pendiente de publicación

 

Percepción de la mujer con dermatitis atópica moderada-grave en la planificación familiar

Promotor: Grupo andaluz de Dermatitis atópica

Investigador Principal: Sara Alcántara Luna. Hospital Juan Ramon Jiménez

IP local: Ricardo Ruiz Villaverde

Concluido y pendiente de publicación

 

Alcantara-Luna S, Ruiz-Villaverde R, Domínguez-Cruz J, Galán-Gutiérrez M, Navarro-Triviño F, Pereyra-Rodriguez JJ, Armario-Hita JC. Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning. Int J Environ Res Public Health. 2022 Aug 29;19(17):10753. doi: 10.3390/ijerph191710753. PMID: 36078468; PMCID: PMC9517831.

 

Unidad de Psoriasis

 

A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study

Promotor: Almirall

Codigo: M-14745-47

Investigador principal: José Carlos Ruiz Carrascosa

En activo

 

Estudio IMPULSE: “A non-interventional, multicentre study to characterise the clinical characteristics, disease burden, and unmet medical needs of Generalized Pustular Psoriasis (GPP) patients in Spain”. IMPULSE study (IMPacto Psoriasis pUstuLoSa generalizada en España).

Promotor: Boehringer Ingelheim

Código protocolo: 1368-0103

IP local. Ricardo Ruiz Villaverde

Concluido

 

"Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)"

Promotor: Abbvie

Codigo: Protocolo P20-441

Investigador principal: José Carlos Ruiz Carrascosa

En Activo

 

 

Última Actualización de la Página: 22/06/2026 16:39:17